Aadi bioscience presents new subgroup analysis of patients with advanced malignant pecoma of gynecologic origin treated with nab-sirolimus at society of gynecologic oncology (sgo)

Subgroup experienced efficacy and safety consistent with overall study population advanced malignant pecoma tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in ampect additional data presented highlight nab-sirolimus as potential approach for mtor-driven gynecologic cancers los angeles , march 17, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mtor pathway, today announced patients in the ampect trial whose malignant perivascular epithelioid cell tumor (pecoma) had gynecologic origins experienced efficacy and safety consistent with the overall study population. the ampect trial formed the basis for the fda approval of the company's nab-sirolimus, fyarro®, for advanced malignant pecoma regardless of mutational status.
AADI Ratings Summary
AADI Quant Ranking